Loading...
•
Dec 31, 2020
Cerus Q4 2020 Earnings Report
Cerus Corporation announced record Q4 and full year financial results.
Key Takeaways
Cerus Corporation reported record total fourth quarter revenues of $33.6 million. Product revenue during the fourth quarter of 2020 was $28.2 million, compared to $20.9 million during the same period in 2019. Government contract revenue primarily from the BARDA agreement was $5.4 million during the fourth quarter of 2020, compared to $5.6 million during the same period in 2019. Net loss for the fourth quarter of 2020 was $14.4 million, compared to a net loss of $16.9 million for the fourth quarter of 2019.
Record total fourth quarter and full year 2020 revenues of $33.6 million and $114.2 million, respectively.
Provided 2021 annual product revenue guidance of $106 million to $110 million, representing an approximately 15% to 20% increase over 2020 reported product revenue.
Received FDA approval for the INTERCEPT Blood System for Cryoprecipitation.
Ended 2020 with cash, cash equivalents, and short-term investments of $133.6 million at December 31, 2020.
Cerus
Cerus
Cerus Revenue by Segment
Cerus Revenue by Geographic Location
Revenue by Segment
Product Revenue
CapyFin.comGovernment Contract Revenue
CapyFin.comRevenue by Geographic Location
North America Revenue
CapyFin.comEurope, Middle East and Africa Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
The Company expects 2021 product revenue to be in the range of $106 million to $110 million. The guidance range represents approximately 15% to 20% growth compared to 2020 reported product revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income